(Reuters) -Vertex Pharmaceuticals said on Wednesday its drug, VX-548, was successful in reducing nerve pain in patients in a mid-stage trial.
Treatment with the drug resulted in a statistically significant reduction in weekly average of daily pain intensity, as measured on a scale at 12 weeks.
The trial studied the non-opioid pain drug in patients with diabetic peripheral neuropathy, a type of nerve damage caused by high blood sugar.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
